The use of B-type natriuretic peptide in the diagnosis of acute dyspnoea.

B-type natriuretic peptide (BNP) and NT-proBNP are currently the most prominent members of the natriuretic peptide family. These markers are secreted from both the left and the right cardiac ventricle in response to ventricular volume expansion and pressure overload. Recent studies have suggested that these neurohormones are reliably elevated in the setting of congestive heart failure and may be very helpful in its diagnosis. The use of rapid BNP testing in addition to clinical judgement increased the accuracy of the clinical evaluation. The B-Type Natriuretic Peptide for Acute Shortness of Breath Evaluation (BASEL) study showed that the increase in accuracy offered by rapid BNP testing resulted in a significant reduction of hospitalisations, use of intensive care, time to discharge and initial treatment cost.
AuthorsChristian Mueller, Kirsten Laule-Kilian, Andreas Christ, Daniel Staub
JournalClinical laboratory (Clin Lab) Vol. 51 Issue 1-2 Pg. 5-9 ( 2005) ISSN: 1433-6510 [Print] Germany
PMID15719699 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Biomarkers
  • Natriuretic Peptide, Brain
  • Acute Disease
  • Biomarkers (analysis)
  • Clinical Medicine (methods)
  • Dyspnea (diagnosis, etiology)
  • Heart Failure (complications, diagnosis)
  • Humans
  • Natriuretic Peptide, Brain
  • Pulmonary Disease, Chronic Obstructive (complications, diagnosis)
  • Reference Values

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: